Back to Authors

Bragg, S. M.

A5033887140 | I168537998

Mayo Clinic

Eli Lilly (United States)

Citations 1

Efficacy of Mirikizumab in Comparison to Ustekinumab in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3 VIVID-1 Study

Zeitschrift für Gastroenterologie | November 27, 2025 | Volume: 62 | Issue: 05 | Pages: e481-e482

10.1055/s-0044-1786891